BSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹733.15
- Market cap
- ₹11,539 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 39.6×Sector 45.9×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27: revenue INR 1,342 cr (+31.9% YoY), EBITDA INR 195 cr (14.5% margin), PAT INR 115 cr (+168.3% YoY). CDMO-led growth; API losses narrowing.
Akums Drugs & Pharmaceuticals Q2 FY27 Results: Net Profit ₹114.6 Cr, Up 168.4% YoY
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,342 Cr (+31.9% YoY) and net profit of ₹114.6 Cr (+168.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹114.6 Cr · +168.4% YoY
Akums Drugs & Pharmaceuticals Management Change
Akums Drugs announced the resignation of Mr. Sunil Jaiswal, SVP R&D and Senior Management Personnel, effective 31 October 2026. The resignation was submitted on 5 August 2026 citing family commitments.
Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Legal & Regulatory
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
- Value
- ₹52.75 Cr
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing notes the removal of two entities from the promoter group.
Other results update announcements
All →HLE Glascoat Results Update
HLE Glascoat reported Q2 FY27 revenue of ₹346.7 Crore, up 15.3% quarter on quarter. Its order book reached a record ₹1,087.3 Crore.
BLS E-Services Results Update
BLS E-Services issued a press release on Q2 and H1 FY27 results. Q2 total income rose 55.1% to Rs. 428 Crores, with PAT of Rs. 20.5 Crores.
Atharva Poly-Plast Results Update
Atharva Poly-Plast reported H1 FY27 revenue of ₹36.69 Crore, up 77.5% year on year. EBITDA margin fell to 20.3% from 35.7% as raw material costs rose.
Krsnaa Diagnostics Results Update
Krsnaa Diagnostics reported record Q2 revenue of Rs 2,710 million, up 32% year on year. H1 PAT fell to Rs 411 million on Rajasthan project costs.
ITC Results Update
ITC's media statement highlights Q2 FY27 results, with consolidated revenue up 19% YoY and EBITDA margin up 50 bps. It accompanies the unaudited results and presentation filed on 2 November 2026.
Lehar Footwears Results Update
Lehar Footwears published Q2FY27 results highlights, with revenue and profit down year-on-year. The Kundli facility lifted monthly capacity to 2.5 lakh pairs.
- sports footwear production capacity
- 2.5 lakh pairs per month